Kimia Farma Persero Tbk (KAEF)
Jakarta Exchange · Indonesia · prices in IDR · close of 23 Oct 2026
Key indicators
| Last close | IDR 374.00 |
|---|---|
| 52-week range | 324.00 – 785.00 |
| Return, 1 month / 3 months | −13.4% / −18.0% |
| Return, 1 year / 3 years | −38.2% / −47.3% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 53.2% |
| Worst drawdown (1 year) | -52.7% |
| Average daily value traded | 1,117.51M IDR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kimia Farma Persero Tbk is an Indonesian pharmaceutical company owned by the state. It makes prescription medicines, over-the-counter drugs, herbal products and other health-related goods at its manufacturing plants, and it runs a chain of pharmacies and health clinics serving customers across the country. The company also provides laboratory testing and other health services. Its headquarters are in Jakarta, and its products reach hospitals, doctors, pharmacies and individual consumers throughout Indonesia.
Kimia Farma Persero Tbk trades under the code KAEF on the Jakarta Exchange in Indonesia, with its price quoted in Indonesian rupiah (IDR). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kimia Farma Persero Tbk (KAEF) trades on the Jakarta Exchange in Indonesia. It last closed at IDR 374.00 on 23 October 2026.
Its price-based Market X-Ray is 42 out of 100 (a weak price profile), ranking 591 of 923 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 38.2% and over the last three months it fell 18.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Jakarta Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 36 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -20.9% | ||
| From 52-week high | -47.7% | ||
| Momentum | 27 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -18.0% | ||
| 6-month return | -27.4% | ||
| 12-month return, skipping the last month | -28.6% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 53.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -52.7% | ||
| Liquidity | 54 · Fair | Moderate trading activity. | |
| Average daily value traded | 1,117.51M IDR | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +7.5% |
|---|---|
| 1 month | −13.4% |
| 3 months | −18.0% |
| 6 months | −27.4% |
| 1 year | −38.2% |
| 3 years | −47.3% |
| 5 years | −84.3% |
Signals
| 50-day / 200-day average | 425.90 / 472.70 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 21.15 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 May 2022 | IDR 16.3274 |
| 7 May 2021 | IDR 1.2704 |
| 16 May 2019 | IDR 14.9800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Jakarta Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.